Market Overview

UPDATE: Biogen Idec Posts Downbeat Q4 Profit, Issues Weak 2013 Profit Forecast

Related BIIB
AbbVie Candidate in Pivotal Study - Analyst Blog
Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog
Don't Panic Over Recent Tech Turmoil (Fox Business)

Biogen Idec (NASDAQ: BIIB) reported a 2.7% drop in its fourth-quarter earnings.

Biogen expects 2013 adjusted earnings of $7.15 to $7.25 per share on around 10% rise in revenue. However, analysts were expecting a profit of $7.27 per share on 9% revenue growth.

Biogen's quarterly profit fell to $292.1 million, or $1.23 per share, from $300.2 million, or $1.22 per share, in the year-ago period. Excluding one-time items, it earned $1.40 per share.

Its revenue rose 6.9% to $1.42 billion. However, analysts expected earnings of $1.46 per share on revenue of $1.39 billion.

Biogen shares closed at $146.20 on Friday.

Posted-In: profitEarnings News Guidance

 

Most Popular

Related Articles (BIIB)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free